GenSight Biologics to Hold its Combined General Meeting on May 19, 2026

About this update from Gensight Biologics Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/de3bb0d65dc904c04eab13559d307738"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AKaTyflF3Jml58vMiEsvYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwOA--/https://media.zenfs.com/en/business-wire.com/de3bb0d65dc904c04eab13559d307738","width":480,"height":204},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/0tF5iSPohkLj.F1G23gW1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI3Mg--/https://media.zenfs.com/en/business-wire.com/de3bb0d65dc904c04eab13559d307738","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Combined General Meeting on May 19, 2026","length":40,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Key operational developments in 2025 and 2026","length":45,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":85,"olType":false},{"type":"text","content":"PARIS, May 18, 2026--(BUSINESS WIRE)--Regulatory News:","length":54,"tagName":"p"},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assemblée générale 2026.","length":485,"tagName":"p"},{"type":"text","content":"On this occasion, Laurence Rodriguez, Chief Executive Officer, will present an overview of the achievements in fiscal year 2025 as well as the key priorities for the current fiscal year.","length":186,"tagName":"p"},{"type":"text","content":"2025 Key Highlights","length":19,"tagName":"p"},{"type":"text","content":"Fiscal year 2025 was marked by a series of financing rounds that supported operations around the granting of a Named Patient Early Access Program (AAC) in France, as well as early access authorizations in the United States in November and in Israel in December 2025. These financing rounds, together with the arrival of new investors and the support of...

More updates from Gensight Biologics Sa